摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-({[(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)oxy]acetyl}amino)benzoic acid | 845829-85-8

中文名称
——
中文别名
——
英文名称
2-({[(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)oxy]acetyl}amino)benzoic acid
英文别名
2-[[2-[(2,2-Dimethyl-3,4-dihydrochromen-6-yl)oxy]acetyl]amino]benzoic acid
2-({[(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)oxy]acetyl}amino)benzoic acid化学式
CAS
845829-85-8
化学式
C20H21NO5
mdl
——
分子量
355.39
InChiKey
KGPPRZXODXBMTQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    26
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    84.9
  • 氢给体数:
    2
  • 氢受体数:
    5

文献信息

  • Anthranilic acid derivatives and their use as activators of the hm74a receptor
    申请人:Campbell Matthew
    公开号:US20070191378A1
    公开(公告)日:2007-08-16
    Therapeutically active anthranilic acid derivatives of Formula (I), processes for the preparation of said derivatives, pharmaceutical formulations containing the compounds and the use of the compounds in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which activation of the receptor will be beneficial, are disclosed.
    本文披露了公式(I)的治疗活性酸衍生物,制备该衍生物的过程,含有该化合物的制药配方以及化合物在治疗中的使用,特别是在治疗HM74A受体欠活化导致疾病或激活该受体将有益的疾病中的使用。
  • ANTHRANILIC ACID DERIVATIVES AND THEIR USE AS ACTIVATORS OF THE HM74A RECEPTOR
    申请人:SMITHKLINE BEECHAM CORPORATION
    公开号:EP1689699A2
    公开(公告)日:2006-08-16
  • [EN] ANTHRANILIC ACID DERIVATIVES AND THEIR USE AS ACTIVATORS OF THE HM74A RECEPTOR<br/>[FR] COMPOSES CHIMIQUES
    申请人:SMITHKLINE BEECHAM CORP
    公开号:WO2005016867A2
    公开(公告)日:2005-02-24
    Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2 and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which activation of the receptor will be beneficial, are disclosed.
查看更多